Estefania Diaz-Mesa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Estefania Diaz-Mesa has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Armando Luis Morera-Fumero
Universidad de la Laguna, San Cristobal de La Laguna, Spain, Spain
3 shared publications - María Lourdes Fernandez-Lopez
Department of Internal Medicine, Dermatology, and Psychiatry, University of La Laguna (ULL), 38320 Santa Cruz de Tenerife, Canary Islands, Spain
3 shared publications - Pedro Abreu-González
Unit of Physiology, Department of Basic Medical Sciences, University of La Laguna, 38200 Tenerife, Spain
3 shared publications - José J. Tascón-Cervera
Department of Internal Medicine, Dermatology, and Psychiatry, University of La Laguna, 38200 Tenerife, Canary Islands, Spain
2 shared publications - Silvia Yelmo-Cruz
Department of Psychiatry, University Hospital of the Canary Islands, 38320 Tenerife, Canary Islands, Spain
2 shared publications - Silvia Yelmo-Cruz
Department of Psychiatry, Canary Islands University Hospital, 38320 Tenerife, Canary Islands, Spain
1 shared publication
Latest Publications
- Open Access
- 2 October 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (10) , 1438
Serum Melatonin at Admission and Discharge in Schizophrenia: A Prospective Longitudinal Controlled Study
Schizophrenia is associated with circadian and neuroendocrine disturbances, but whether circulating melatonin changes with acute clinical state remains uncertain. This prospective longitudinal controlled study measured serum melatonin at 12:00 and 00:00 in 43 hospitalized patients after admission and before discharge, and during one session in 42 healthy controls. Psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). Nonparametric comparisons used family-specific Holm adjustment; exploratory correlations used false-discovery-rate control. In comparisons without covariate adjustment, midday concentrations were higher in patients at admission and discharge (Holm p = 0.013 and 0.007), but the differences did not remain significant after Holm correction in exploratory models adjusted for BMI, age, and sex (29 patients and 40 controls). Median within-patient changes were −0.14 pg/mL at 12:00 (95% CI −0.27 to 0.74) and 0.00 pg./mL at 00:00 (95% CI −2.00 to 6.35); both Holm p = 1.000. Total PANSS decreased by a median of 14 points among 24 complete pairs. No change-PANSS correlation survived multiplicity correction. Two daily samples demonstrate a midday–midnight concentration difference but cannot characterize circadian phase, amplitude, or total secretion. No short-term melatonin change was detected during hospitalization; this does not establish equivalence or confirm or exclude trait-biomarker status. State-marker utility remains uncertain, and patient–control differences may reflect medication, smoking, or confounding by assay plate.
- 2 October 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (10) , 1438
Open AccessSerum Melatonin at Admission and Discharge in Schizophrenia: A Prospective Longitudinal Controlled Study
Schizophrenia is associated with circadian and neuroendocrine disturbances, but whether circulating melatonin changes with acute clinical state remains uncertain. This prospective longitudinal controlled study measured serum melatonin at 12:00 and 00:00 in 43 hospitalized patients after admission and before discharge, and during one session in 42 healthy controls. Psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). Nonparametric comparisons used family-specific Holm adjustment; exploratory correlations used false-discovery-rate control. In comparisons without covariate adjustment, midday concentrations were higher in patients at admission and discharge (Holm p = 0.013 and 0.007), but the differences did not remain significant after Holm correction in exploratory models adjusted for BMI, age, and sex (29 patients and 40 controls). Median within-patient changes were −0.14 pg/mL at 12:00 (95% CI −0.27 to 0.74) and 0.00 pg./mL at 00:00 (95% CI −2.00 to 6.35); both Holm p = 1.000. Total PANSS decreased by a median of 14 points among 24 complete pairs. No change-PANSS correlation survived multiplicity correction. Two daily samples demonstrate a midday–midnight concentration difference but cannot characterize circadian phase, amplitude, or total secretion. No short-term melatonin change was detected during hospitalization; this does not establish equivalence or confirm or exclude trait-biomarker status. State-marker utility remains uncertain, and patient–control differences may reflect medication, smoking, or confounding by assay plate.
- Open Access
- 28 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7542
Longitudinal Changes in Serum Interleukin-33 Levels During Acute Psychotic Relapse and Clinical Improvement in Schizophrenia: An Admission-Discharge Study
Background/Objectives: Schizophrenia pathophysiology has been linked to immune dysregulation, but the role of interleukin-33 (IL-33) during acute psychotic relapse remains insufficiently investigated. This exploratory admission–discharge study aimed to evaluate serum IL-33 levels in inpatients with paranoid schizophrenia and in healthy controls. Methods: Serum IL-33 was measured at midday (12:00 h) and midnight (24:00 h) in 21 inpatients with paranoid schizophrenia and 21 age- and sex-matched healthy controls (HC). Patients were sampled at admission and discharge. HC underwent one sampling day, with blood collected at both 12:00 h and 24:00 h, during the interval between the patients’ admission and discharge assessments. Psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). Results: PANSS positive and general psychopathology scores decreased from admission to discharge (p < 0.001 and p = 0.008, respectively). Serum IL-33 concentrations were descriptively higher in patients than in HC, but between-group differences were not statistically significant. Midnight serum IL-33 increased from admission to discharge (214.9 ± 358.0 vs. 241.2 ± 379.4 pg/mL; p = 0.028), whereas the midday change was nonsignificant. Age was inversely correlated with IL-33 in patients; associations with antipsychotic dosage and sex were not statistically significant. Conclusions: The midnight increase in IL-33 accompanied clinical improvement, but medication, hospitalization, age, and smoking remain potential confounders. These exploratory findings warrant replication and do not establish IL-33 as a diagnostic or state biomarker.
- 28 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7542
Open AccessLongitudinal Changes in Serum Interleukin-33 Levels During Acute Psychotic Relapse and Clinical Improvement in Schizophrenia: An Admission-Discharge Study
Background/Objectives: Schizophrenia pathophysiology has been linked to immune dysregulation, but the role of interleukin-33 (IL-33) during acute psychotic relapse remains insufficiently investigated. This exploratory admission–discharge study aimed to evaluate serum IL-33 levels in inpatients with paranoid schizophrenia and in healthy controls. Methods: Serum IL-33 was measured at midday (12:00 h) and midnight (24:00 h) in 21 inpatients with paranoid schizophrenia and 21 age- and sex-matched healthy controls (HC). Patients were sampled at admission and discharge. HC underwent one sampling day, with blood collected at both 12:00 h and 24:00 h, during the interval between the patients’ admission and discharge assessments. Psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). Results: PANSS positive and general psychopathology scores decreased from admission to discharge (p < 0.001 and p = 0.008, respectively). Serum IL-33 concentrations were descriptively higher in patients than in HC, but between-group differences were not statistically significant. Midnight serum IL-33 increased from admission to discharge (214.9 ± 358.0 vs. 241.2 ± 379.4 pg/mL; p = 0.028), whereas the midday change was nonsignificant. Age was inversely correlated with IL-33 in patients; associations with antipsychotic dosage and sex were not statistically significant. Conclusions: The midnight increase in IL-33 accompanied clinical improvement, but medication, hospitalization, age, and smoking remain potential confounders. These exploratory findings warrant replication and do not establish IL-33 as a diagnostic or state biomarker.
- Open Access
- 6 August 2026
- Published by MDPI AG in Preprints.org
Longitudinal Changes in Serum Interleukin-33 Levels During Acute Psychotic Relapse and Recovery in Schizophrenia: An Admission-Discharge Study
Immune-inflammatory dysregulation plays a central role in the pathophysiology of schizophrenia (SCZ). Interleukin-33 (IL-33), a pleiotropic alarmin cytokine of the IL-1 family, modulates neuroimmune communication, glial activation, and tissue repair, yet its involvement in psychotic disorders remains poorly characterized. This study examined serum IL-33 concentrations in 21 patients experiencing an acute psychotic relapse and 21 age- and sex-matched healthy controls (HC). Using a longitudinal design, we measured serum IL-33 by ELISA at 12:00 h and 24:00 h on the day after admission and the day before discharge in patients, alongside comprehensive clinical assessment with the Positive and Negative Syndrome Scale (PANSS). Patients with SCZ exhibited significantly lower IL-33 levels than HC at all time points (p < 0.05). Notably, IL-33 concentrations increased significantly at midnight from admission to discharge (p = 0.028), paralleling clinical improvement in PANSS positive and general psychopathology scores. A robust inverse correlation between age and IL-33 levels was observed in both patients and controls (p < 0.05), independent of sex, smoking status, sampling time, and antipsychotic dosage. These findings provide the first longitudinal evidence that IL-33 is reduced during acute psychotic episodes and rises in association with clinical recovery, supporting its role as a state-dependent biomarker. Our results highlight the involvement of alarmin signalling in the neuroimmune dysregulation underlying psychotic relapse and underscore the importance of age as a critical covariate in immunopsychiatric research.
- 6 August 2026
- Published by MDPI AG in Preprints.org
Open AccessLongitudinal Changes in Serum Interleukin-33 Levels During Acute Psychotic Relapse and Recovery in Schizophrenia: An Admission-Discharge Study
Immune-inflammatory dysregulation plays a central role in the pathophysiology of schizophrenia (SCZ). Interleukin-33 (IL-33), a pleiotropic alarmin cytokine of the IL-1 family, modulates neuroimmune communication, glial activation, and tissue repair, yet its involvement in psychotic disorders remains poorly characterized. This study examined serum IL-33 concentrations in 21 patients experiencing an acute psychotic relapse and 21 age- and sex-matched healthy controls (HC). Using a longitudinal design, we measured serum IL-33 by ELISA at 12:00 h and 24:00 h on the day after admission and the day before discharge in patients, alongside comprehensive clinical assessment with the Positive and Negative Syndrome Scale (PANSS). Patients with SCZ exhibited significantly lower IL-33 levels than HC at all time points (p < 0.05). Notably, IL-33 concentrations increased significantly at midnight from admission to discharge (p = 0.028), paralleling clinical improvement in PANSS positive and general psychopathology scores. A robust inverse correlation between age and IL-33 levels was observed in both patients and controls (p < 0.05), independent of sex, smoking status, sampling time, and antipsychotic dosage. These findings provide the first longitudinal evidence that IL-33 is reduced during acute psychotic episodes and rises in association with clinical recovery, supporting its role as a state-dependent biomarker. Our results highlight the involvement of alarmin signalling in the neuroimmune dysregulation underlying psychotic relapse and underscore the importance of age as a critical covariate in immunopsychiatric research.